



Cara Therapeutics
Investor Relations Department
107 Elm St. 9th Flr
Stamford, CT 06902
United States

Visit IR website [↗](#)
Sign-up for Email alerts [↗](#)

NASDAQ: CARA

Last Trade:	26.42
Trade Time:	4:00 PM ET Jun 27, 2017
Change:	1.01 ▲ (+3.975%)
Day Range	25.70 - 28.50
52-Week Range	4.60 - 25.63
Volume	7,967,124

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Cara Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors.

We are developing a novel and proprietary class of product candidates that target the body's peripheral nervous system and have demonstrated efficacy in patients with moderate-to-severe pain without inducing many of the undesirable side effects typically associated with currently available pain therapeutics. Our most advanced product candidate, intravenous, or I.V... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Jun 23, 2017**
[Cara Receives Breakthrough Therapy Designation from FDA for I.V. CR845 for the Treatment of Chronic Kidney Disease-Associated Pruritus in Hemodialysis Patients](#)
- Jun 21, 2017**
[Cara Therapeutics Reports Continuation of Phase 3 Trial of I.V. CR845 in Postoperative Pain Following Interim Assessment](#)
- May 17, 2017**
[Cara Therapeutics to Present at the 17th Annual Conference on Pain Therapeutics](#)
- May 12, 2017**
[Cara Therapeutics to Host KOL Meeting on Chronic Kidney Disease-Associated Pruritus on May 16, 2017](#)
- May 4, 2017**
[Cara Therapeutics Reports First Quarter 2017 Financial Results](#)

Financials [\[View all \]](#)

- Mar 10, 2017**
[Annual Report \(10-K\)](#)
- May 10, 2017**
[Proxy Statement \(DEF 14A\)](#)
- May 4, 2017**
[Quarterly Report \(10-Q\)](#)
- Nov 4, 2016**
[Quarterly Report \(10-Q\)](#)
- Aug 4, 2016**
[Quarterly Report \(10-Q\)](#)